--- title: "EloraTZP: Eloralintide Plus Tirzepatide Trial Results" url: https://www.bodyhackguide.co/blog/eloratzp-eloralintide-tirzepatide description: "EloraTZP results arm by arm: up to 23.3% weight loss vs 14.8% on tirzepatide 15 mg in type 2 diabetes, side effects, quit rates and the Phase 3 plan." lang: en --- Skip to content Compare notes on r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Compare notes with other researchers. Join r/BodyHackGuide (https://reddit.com/r/bodyhackguide) Research 9 min read Oct 25, 2026 Fact-checked (https://www.bodyhackguide.co/editorial-standards) # EloraTZP: Eloralintide Plus Tirzepatide Trial Results EloraTZP pairs eloralintide with tirzepatide. In a type 2 diabetes Phase 2b the top arm lost 23.3% at 48 weeks on the efficacy estimand. Phase 3 is next. B BioChonch Last checked Oct 25, 2026 Evidence notes from published research and trial registries. Educational information, not medical advice. Key Takeaway **EloraTZP is two Lilly drugs given together: eloralintide, a selective amylin receptor agonist, and tirzepatide, the GIP and GLP-1 receptor agonist sold as Mounjaro and Zepbound.** In a 48-week Phase 2b trial of 367 adults with obesity or overweight and type 2 diabetes, the top arm, eloralintide 9 mg plus tirzepatide 15 mg, lost 23.3% of body weight on average. Tirzepatide 15 mg alone lost 14.8% and placebo 3.0%. Those are efficacy-estimand figures, which assume everyone stayed on treatment (Lilly's results release (https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html)). In the combination arms, 10.8% to 27.0% of participants stopped treatment because of adverse events, depending on the arm. The trial used two separate injections; Phase 3 moves to one co-formulated shot. EloraTZP is not approved anywhere, and this page covers what its trials have shown, not how to use either drug. ## The name, and one shot or two The name joins Elora, for eloralintide (Lilly code LY3841136), to TZP, Lilly's shorthand for tirzepatide. Unlike amycretin (https://www.bodyhackguide.co/blog/amycretin-trial-evidence), it is not one new molecule. Co-administered or co-formulated? Both, at different stages. In Phase 2b the drugs were given as separate injections (https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html). The Phase 3 records describe an "eloralintide and tirzepatide coformulation" coded LY900043 (https://clinicaltrials.gov/study/NCT07881432). A Phase 1 relative-bioavailability study of the pair, NCT06916065 (https://clinicaltrials.gov/study/NCT06916065), finished in January 2026 without saying which formulation it used. Eloralintide is a once-weekly injection with a half-life of about 14 days (Phase 1 paper (https://pmc.ncbi.nlm.nih.gov/articles/PMC12992164/)). Our eloralintide (https://www.bodyhackguide.co/compound/eloralintide) and tirzepatide (https://www.bodyhackguide.co/compound/tirzepatide) pages cover each drug on its own. ## How the Phase 2b trial was set up NCT06603571 (https://clinicaltrials.gov/study/NCT06603571) ran in the US and Argentina; Lilly presented it at EASD in Milan on September 30, 2026 (schedule (https://www.prnewswire.com/news-releases/lilly-to-present-new-data-on-foundayo-retatrutide-and-eloratzp-at-easd-2026-as-it-strives-to-change-the-course-of-cardiometabolic-health-302878341.html)). | Design point | NCT06603571 | | --- | --- | | Population | Adults with a BMI of 27 or more and type 2 diabetes, HbA1c 7.0% to 10.5%, on diet and exercise or metformin with or without an SGLT2 inhibitor | | Baseline | 105.4 kg (232.4 lb) and an A1C of 8.1% on average | | Arms | Ten, randomized in equal numbers: placebo, three eloralintide doses alone, tirzepatide 15 mg, four pairings, and an arm adding eloralintide to tirzepatide at week 24 (3 mg, then 6 mg) | | Escalation | Pairings started at eloralintide 1 or 3 mg plus tirzepatide 2.5 mg and stepped up every four weeks | | Primary endpoint | Percent weight change at week 48, EloraTZP against placebo; comparisons with tirzepatide alone were secondary | Sources: registry (https://clinicaltrials.gov/study/NCT06603571) and Lilly (https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html). Lilly reported nothing from the tenth arm. Ten arms from 367 people means about 37 per arm, which matters for every figure below. ## EloraTZP results by arm | Arm, weekly doses tested in NCT06603571 | Mean weight loss | Pounds lost | A1C drop, points | | --- | --- | --- | --- | | Eloralintide 3 mg + tirzepatide 5 mg | 13.2% | 30.7 | 2.2 | | Eloralintide 6 mg + tirzepatide 5 mg | 19.4% | 45.1 | 2.7 | | Eloralintide 6 mg + tirzepatide 10 mg | 19.9% | 46.2 | 2.6 | | Eloralintide 9 mg + tirzepatide 15 mg | 23.3% | 54.1 | 2.9 | | Tirzepatide 15 mg | 14.8% | 34.4 | 2.4 | | Eloralintide 3 mg | 8.2% | 19.1 | 1.1 | | Eloralintide 6 mg | 12.3% | 28.6 | 1.4 | | Eloralintide 9 mg | 11.1% | 25.8 | 1.3 | | Placebo | 3.0% | 7.0 | 0.3 | Source: Lilly, September 30, 2026 (https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html), 48 weeks, efficacy estimand. The release gives no confidence intervals, and PubMed listed no paper on this trial as of October 24. ## What the table does and does not show The 23.3% headline is not the most telling number. Look at eloralintide 6 mg plus tirzepatide 5 mg: 19.4%, against 14.8% for tirzepatide 15 mg, on a third of the tirzepatide dose (Lilly (https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html)). If Phase 3 repeats that, amylin could buy more weight loss with less incretin. For now it is a secondary comparison between two small arms. Eloralintide alone looked weaker here than in its first Phase 2. In adults without diabetes, 9 mg produced 20.1% at 48 weeks (Lancet trial (https://pubmed.ncbi.nlm.nih.gov/41207310/), our phase 2 review (https://www.bodyhackguide.co/blog/eloralintide-phase-2-results)); here the same dose produced 11.1%, no better than 6 mg. Diabetes explains part of that gap, because it blunts weight loss across the class. Tirzepatide 15 mg gave 20.9% in SURMOUNT-1 (https://pubmed.ncbi.nlm.nih.gov/35658024/), which excluded diabetes, and 14.7% in SURMOUNT-2 (https://pubmed.ncbi.nlm.nih.gov/37385275/), which required it, both at 72 weeks. Then the estimand. FDA's draft obesity guidance (https://www.fda.gov/media/71252/download) asks for treatment-policy analyses that count everyone randomized, and with up to 27.0% stopping treatment for adverse events, those figures are likely to come in lower, by an amount nobody outside Lilly knows. ## Side effects and who stopped Lilly says gastrointestinal events were the most common, mostly mild or moderate, clustered in dose escalation, and more frequent in the combination arms than with either drug alone. Discontinuation for adverse events was 10.8% to 27.0% with EloraTZP, 0% to 10.8% with eloralintide alone, 2.9% with tirzepatide and 16.7% with placebo (Lilly (https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html)). That placebo figure is a warning about small arms: more placebo participants stopped over adverse events than tirzepatide participants did. If arms stayed near equal size, 27.0% is roughly ten people and 2.9% roughly one. Until a full paper gives confidence intervals, we treat every per-arm rate here as soft. Lilly says Phase 3 will use an "optimized escalation schedule," which suggests it sees the step-up pace as part of the problem. The release leaves out per-arm nausea and fatigue, which arm reached 27.0%, and heart rate. Eloralintide's own trials say where to look. In the monotherapy Phase 2, fatigue hit 43% on 9 mg against 12% on placebo, and nausea 64% on 6 mg against 14% (Lancet (https://pubmed.ncbi.nlm.nih.gov/41207310/)). Heart rate is harder to call. In Phase 1, mean pulse fell 14.4 beats per minute on 12 mg against 3.4 on placebo at week 12, with no symptomatic bradycardia (Phase 1 paper (https://pmc.ncbi.nlm.nih.gov/articles/PMC12992164/)). GLP-1 drugs tend to raise heart rate (2026 review (https://pubmed.ncbi.nlm.nih.gov/42745233/)), so what the pair does to pulse is an open question, and the Phase 2b excluded anyone with a resting pulse under 60 or over 100 (registry (https://clinicaltrials.gov/study/NCT06603571)). The same Phase 1 logged mood-related events, including depressed mood, in four of 73 people on eloralintide (Phase 1 paper (https://pmc.ncbi.nlm.nih.gov/articles/PMC12992164/)). ## Why pair amylin with an incretin? Amylin is released with insulin after meals. It curbs glucagon, slows gastric emptying and signals fullness through the brain (Phase 1 paper (https://pmc.ncbi.nlm.nih.gov/articles/PMC12992164/)). GIP and GLP-1 use other receptors, so the effects can stack. CagriSema, an amylin analog paired with the GLP-1 drug semaglutide, showed they do, and Lilly's researchers note that pairing also "brings additivity for gastrointestinal adverse events" (same paper (https://pmc.ncbi.nlm.nih.gov/articles/PMC12992164/)). Lilly's bet is selectivity. In cell assays eloralintide activated the human amylin 1 receptor about 12 times more potently than the calcitonin receptor, and in rats it caused less conditioned taste avoidance than cagrilintide (discovery paper (https://doi.org/10.1016/j.molmet.2025.102271)). Lilly says EloraTZP has "minimal activity at the calcitonin receptor" (Lilly (https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html)). No human trial has tested that head to head; see eloralintide vs cagrilintide (https://www.bodyhackguide.co/blog/eloralintide-vs-cagrilintide) and amylin analogs compared (https://www.bodyhackguide.co/blog/amylin-analogs-compared). The other half of the bet is the partner. In the open-label REDEFINE 4, people on CagriSema lost 23.0% against 25.5% on tirzepatide 15 mg at 84 weeks, had everyone stayed on treatment, and missed non-inferiority (Novo Nordisk (https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916501)). Lilly is adding amylin to the incretin CagriSema could not match. A Phase 1 result at EASD 2026 showed 17% weight loss at 16 weeks with eloralintide 3 mg on top of tirzepatide 5 mg, against 10% on tirzepatide 5 mg alone (Lilly (https://www.prnewswire.com/news-releases/lilly-to-present-new-data-on-foundayo-retatrutide-and-eloratzp-at-easd-2026-as-it-strives-to-change-the-course-of-cardiometabolic-health-302878341.html)). ## EloraTZP next to other diabetes trials Length, estimand and populations differ, so read the rows as context rather than a ranking. | Trial | Drugs, top dose tested | Weeks | Estimand | Mean weight loss | Placebo | | --- | --- | --- | --- | --- | --- | | NCT06603571 (https://clinicaltrials.gov/study/NCT06603571), Phase 2b | Eloralintide 9 mg + tirzepatide 15 mg | 48 | Efficacy | 23.3% | 3.0% | | SURMOUNT-2 (https://pubmed.ncbi.nlm.nih.gov/37385275/), Phase 3 | Tirzepatide 15 mg | 72 | Treatment-regimen | 14.7% | 3.2% | | REDEFINE 2 (https://pubmed.ncbi.nlm.nih.gov/40544432/), Phase 3 | Cagrilintide 2.4 mg + semaglutide 2.4 mg | 68 | Treatment-policy | 13.7% | 3.4% | CagriSema is much further along. Novo announced its FDA filing on December 18, 2025 (https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916470), ten months before the EloraTZP Phase 3 trials appeared on the registry. ## Without diabetes, and what comes next Apart from that short Phase 1 result, every EloraTZP figure comes from people with type 2 diabetes. The real test for everyone else is AMPLIFY-1 (NCT07881432 (https://clinicaltrials.gov/study/NCT07881432)): about 2,115 adults with a BMI of 35 or more and no diabetes, randomized to five EloraTZP doses, tirzepatide alone, eloralintide alone or placebo, measured at week 100. That BMI floor sits well above ENLIGHTEN-1's 30, or 27 with a weight-related condition (NCT07321886 (https://clinicaltrials.gov/study/NCT07321886)), which reads like a combination aimed at people with more weight to lose. AMPLIFY-2 (NCT07881458 (https://clinicaltrials.gov/study/NCT07881458)) pits EloraTZP against tirzepatide in about 1,000 adults with type 2 diabetes. It is due to start in November 2026 and AMPLIFY-1 in December; both list primary completion in October 2029 and no milligram doses. Our eloralintide Phase 3 trials and timeline (https://www.bodyhackguide.co/blog/eloralintide-phase-3-trials) lists every registered study and estimates approval timing. No registered trial pairs eloralintide with retatrutide. For the two as single drugs, see eloralintide vs retatrutide (https://www.bodyhackguide.co/blog/eloralintide-vs-retatrutide). ## Sources - Lilly: EloraTZP Phase 2b release (https://www.prnewswire.com/news-releases/lillys-eloratzp-combination-of-eloralintide-and-tirzepatide-delivered-greater-weight-loss-and-a1c-reduction-vs-tirzepatide-15-mg-in-adults-with-obesity-and-type-2-diabetes-302894480.html), EASD 2026 schedule (https://www.prnewswire.com/news-releases/lilly-to-present-new-data-on-foundayo-retatrutide-and-eloratzp-at-easd-2026-as-it-strives-to-change-the-course-of-cardiometabolic-health-302878341.html) - Registry records: NCT06603571 (https://clinicaltrials.gov/study/NCT06603571), AMPLIFY-1 (https://clinicaltrials.gov/study/NCT07881432), AMPLIFY-2 (https://clinicaltrials.gov/study/NCT07881458), NCT06916065 (https://clinicaltrials.gov/study/NCT06916065) - Eloralintide papers: Phase 2 (https://pubmed.ncbi.nlm.nih.gov/41207310/), Phase 1 multiple dose (https://pmc.ncbi.nlm.nih.gov/articles/PMC12992164/), discovery (https://doi.org/10.1016/j.molmet.2025.102271) - SURMOUNT-1: https://pubmed.ncbi.nlm.nih.gov/35658024/ , SURMOUNT-2: https://pubmed.ncbi.nlm.nih.gov/37385275/ , REDEFINE 2: https://pubmed.ncbi.nlm.nih.gov/40544432/ - Novo Nordisk: REDEFINE 4 (https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916501), CagriSema FDA filing (https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916470) - FDA draft obesity guidance: https://www.fda.gov/media/71252/download ## Frequently asked Not in Phase 2b, where eloralintide and tirzepatide went in as separate weekly injections. The Phase 3 trials use a single co-formulated product, coded LY900043. ## Related Articles Research ### UBT251: Phase 2 Results and the 19.7% Weight-Loss Claim Read https://www.bodyhackguide.co/blog/ubt251-phase-2-results Research ### Eloralintide: Amylin and the Phase 2 Weight-Loss Results Read https://www.bodyhackguide.co/blog/eloralintide-phase-2-results Research ### P11-4 and Curodont: What Enamel-Repair Trials Show Read https://www.bodyhackguide.co/blog/p11-4-enamel-repair-evidence Research ### Amycretin: What the Trials Actually Show So Far Read https://www.bodyhackguide.co/blog/amycretin-trial-evidence Research ### Petrelintide: ZUPREME-1 Results and the Tolerability Claim Read https://www.bodyhackguide.co/blog/petrelintide-zupreme-1-results Research ### Eloralintide vs Retatrutide: Trials, Doses, Side Effects Read https://www.bodyhackguide.co/blog/eloralintide-vs-retatrutide Research ### Eloralintide Clinical Trials: Phase 3 and Timeline Read https://www.bodyhackguide.co/blog/eloralintide-phase-3-trials Research ### Amylin Analogs and Agonists: Drugs, Trials, Status Read https://www.bodyhackguide.co/blog/amylin-analogs-compared Research ### Eloralintide vs Cagrilintide: Two Amylin Drugs Compared Read https://www.bodyhackguide.co/blog/eloralintide-vs-cagrilintide ## New guides, by email New compound guides and research notes when we publish them. No set schedule. Unsubscribe anytime. No spam. Unsubscribe anytime. Share this article: 𝕏 / Twitter (https://twitter.com/intent/tweet?text=EloraTZP%3A%20Eloralintide%20Plus%20Tirzepatide%20Trial%20Results&url=https%3A%2F%2Fwww.bodyhackguide.co%2Fblog%2Feloratzp-eloralintide-tirzepatide) B BioChonch (https://www.bodyhackguide.co/about)Research editorial Join r/BodyHackGuide on Reddit: https://reddit.com/r/bodyhackguide Join Discord: https://discord.gg/Mhq5UdRYBA | About the author: https://www.bodyhackguide.co/about Back to all articles: https://www.bodyhackguide.co/blog BodyHackGuide (https://www.bodyhackguide.co/) Your biohacking research hub: compound pricing, brain health protocols, dosing tools, and vendor reviews. support@bodyhackguide.co Join our Discord: https://discord.gg/Mhq5UdRYBA r/BodyHackGuide on Reddit: https://reddit.com/r/BodyHackGuide **Affiliate Disclosure:** We rank every vendor on the same public, reproducible methodology (https://www.bodyhackguide.co/vendors/methodology). Full details in our affiliate disclosure (https://www.bodyhackguide.co/affiliate-disclosure). **Research Disclaimer:** All compounds listed are for laboratory and research purposes only. Not for human consumption. This site does not sell or ship any products. Always consult a qualified healthcare professional and comply with local regulations. © 2026 BodyHackGuide. All rights reserved. - Terms: https://www.bodyhackguide.co/terms - Privacy: https://www.bodyhackguide.co/privacy ## Structured data ```json [ { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://www.bodyhackguide.co/" }, { "@type": "ListItem", "position": 2, "name": "Blog", "item": "https://www.bodyhackguide.co/blog" }, { "@type": "ListItem", "position": 3, "name": "EloraTZP: Eloralintide Plus Tirzepatide Trial Results" } ] }, { "@context": "https://schema.org", "@type": "BlogPosting", "headline": "EloraTZP: Eloralintide Plus Tirzepatide Trial Results", "description": "EloraTZP pairs eloralintide with tirzepatide. In a type 2 diabetes Phase 2b the top arm lost 23.3% at 48 weeks on the efficacy estimand. Phase 3 is next.", "datePublished": "2026-10-25T07:28:00Z", "dateModified": "2026-10-25T07:28:00Z", "author": { "@type": "Person", "name": "BioChonch" }, "publisher": { "@type": "Organization", "name": "BodyHackGuide", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/bhglogo.png" } }, "mainEntityOfPage": "https://www.bodyhackguide.co/blog/eloratzp-eloralintide-tirzepatide", "wordCount": 1753, "timeRequired": "PT9M", "articleSection": "Research", "inLanguage": "en-US", "isAccessibleForFree": true, "speakable": { "@type": "SpeakableSpecification", "cssSelector": [ "h1", ".blog-tldr", "article p:first-of-type" ] } }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Is EloraTZP one injection?", "acceptedAnswer": { "@type": "Answer", "text": "Not in Phase 2b, where eloralintide and tirzepatide went in as separate weekly injections. The Phase 3 trials use a single co-formulated product, coded LY900043." } }, { "@type": "Question", "name": "Is EloraTZP approved?", "acceptedAnswer": { "@type": "Answer", "text": "No. It is investigational, and its Phase 3 trials list primary completion in October 2029." } }, { "@type": "Question", "name": "Is eloralintide better than tirzepatide?", "acceptedAnswer": { "@type": "Answer", "text": "No trial shows that. NCT06603571 is the only trial with separate eloralintide and tirzepatide arms to have reported results, and in people with type 2 diabetes eloralintide alone lost 8.2% to 12.3% against 14.8% on tirzepatide 15 mg. In that trial, eloralintide looked more useful as a partner than on its own." } }, { "@type": "Question", "name": "What doses were tested in the Phase 2b trial?", "acceptedAnswer": { "@type": "Answer", "text": "Eloralintide 3, 6 or 9 mg alone, tirzepatide 15 mg alone, and four weekly pairings of eloralintide plus tirzepatide: 3 and 5 mg, 6 and 5 mg, 6 and 10 mg, and 9 and 15 mg. A tenth arm added eloralintide to tirzepatide at week 24. These are doses tested in a trial, not recommendations." } } ] }, { "@context": "https://schema.org", "@type": "Organization", "@id": "https://www.bodyhackguide.co#organization", "name": "BodyHackGuide", "alternateName": "BHG", "url": "https://www.bodyhackguide.co", "logo": { "@type": "ImageObject", "url": "https://www.bodyhackguide.co/logo.png", "width": 512, "height": 512 }, "description": "Evidence-based research reference for peptides and nootropics. 273 compound profiles, interactive dosing calculators, vendor price comparisons, and trust-scored vendor reviews scored on a public, reproducible methodology applied to every vendor. We earn a commission on purchases through some of our links.", "foundingDate": "2024", "founder": { "@id": "https://www.bodyhackguide.co/about#person" }, "sameAs": [ "https://reddit.com/r/BodyHackGuide", "https://reddit.com/r/BrainHackGuide", "https://reddit.com/r/Biohackingher", "https://discord.gg/Mhq5UdRYBA" ], "knowsAbout": [ "Peptide research", "Nootropic research", "Biohacking", "Compound dosing", "Vendor transparency" ], "publishingPrinciples": "https://www.bodyhackguide.co/editorial-standards", "ethicsPolicy": "https://www.bodyhackguide.co/editorial-standards", "diversityPolicy": "https://www.bodyhackguide.co/editorial-standards" } ] ```